Provided by Tiger Fintech (Singapore) Pte. Ltd.

Absci Corporation.

3.14
+0.24008.28%
Post-market: 3.180.0396+1.26%19:59 EDT
Volume:5.13M
Turnover:15.70M
Market Cap:360.65M
PE:-3.36
High:3.21
Open:2.98
Low:2.90
Close:2.90
Loading ...

Company Profile

Company Name:
Absci Corporation.
Exchange:
NASDAQ
Establishment Date:
2011
Employees:
155
Office Location:
18105 SE Mill Plain Boulevard,Vancouver,Washington,United States
Zip Code:
98683
Fax:
- -
Introduction:
Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. It has a collaboration with Memorial Sloan Kettering Cancer Center to discover novel therapeutics using generative AI; with AstraZeneca PLC for AI-driven drug discovery against an oncology target; and with Twist Bioscience Corporation to design a novel therapeutic using generative AI. The company was founded in 2011 and is headquartered in Vancouver, Washington.

Directors

Name
Position
Sean McClain
Chief Executive Officer and Director
Amrit Nagpal
Director
Eli Casdin
Director
Ivana Magovcevic Liebisch
Director
Karen McGinnis
Director
Zachariah Jonasson
Director

Shareholders

Name
Position
Sean McClain
Chief Executive Officer and Director
Andreas Pihl
Chief Operating Officer
Gregory Schiffman
Chief Financial Officer
Matthew Weinstock
Chief Technology Officer
Nikhil Goel
Chief Business Officer
Sarah Korman
General Counsel